Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 21

1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1

Date

21 Oct 2023

Session

Poster session 21

Topics

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Zev Wainberg

Citation

Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10.1016/S0923-7534(23)01930-0

Authors

Z.A. Wainberg1, K. Yamaguchi2, J.A. Ajani3, J. Chao4, M. Moehler5, Y. Kang6, E. Van Cutsem7, P. Yen8, Y. Motii9, D. Zhou10, T. Murias Dos Santos11, K. Shitara12

Author affiliations

  • 1 Medicine Hematology And Oncology, UCLA - David Geffen School of Medicine, 90095 - Los Angeles/US
  • 2 Gastroenterological Chemotherapy Dept., The Cancer Institute Hospital of JFCR, 135-8550 - Koto-ku/JP
  • 3 Gi Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 4 Department Of Medical Oncology, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
  • 5 1. Dept. Medicine, Universitätsmedizin Mainz, 55131 - Mainz/DE
  • 6 Oncology Dept, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 7 Digestive Oncology Department, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 8 Biostatistical Science, AMGEN (Headquarters) - USA, 91320-1799 - Thousand Oaks/US
  • 9 Safety, Amgen Inc - SSF, 94080 - South San Francisco/US
  • 10 Clinical Pharmacology, Amgen Inc - SSF, 94080 - South San Francisco/US
  • 11 Clinical Development, AMGEN (Headquarters) - USA, 91320-1799 - Thousand Oaks/US
  • 12 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1526P

Background

In the phase (ph) 2 FIGHT trial, BEMA+mFOLFOX6 had promising efficacy in patients with FGFR2b-selected G/GEJC. FORTITUDE-102 comprises part 1 (open-label ph1b) evaluated the safety and tolerability of BEMA+mFOLFOX6+NIVO and part 2 (randomized ph3) the safety and efficacy compared with placebo. Here, we present the results of part 1.

Methods

Up to 20 patients (pts) with/without FGFR2b overexpression could be enrolled. The initial dose of BEMA was 15 mg/kg IV Q2W with one 7.5 mg/kg dose on cycle 1 day 8. The dose-limiting toxicity (DLT) period was 28 days. At least 6 pts were treated at a dose level with less than 33% incidence of DLTs to determine the recommended ph3 dose (RP3D). An ad hoc review was performed 6mo after the DLT period.

Results

Eight pts (50-71 y) were enrolled and evaluated for DLTs: 6 pts were men, 4 pts were Asian, and 4 pts were White. No DLTs were reported; no new safety signals were identified. Mean exposures for the first 3 cycles and estimated terminal elimination half-life (7-11 days) were consistent with historical data. No meaningful BEMA exposure changes were observed with the addition of NIVO, indicating no drug interactions. The RP3D was 15 mg/kg Q2W with one 7.5mg/kg dose on cycle 1 day 8. Six mo post-DLT period, the median treatment duration was ∼34 weeks (8-40). Four pts had 6 serious AEs (n=1 AE [hyponatremia] considered BEMA-related); 7 pts had 13 grade ≥3 AEs (n=4 [neutropenia, mucositis, hyponatremia, and delirium] in 2pts considered BEMA-related). Five pts reported 8 ocular AEs of grades ≤2, with a median time to onset of ∼17 weeks. No AEs led to BEMA discontinuation. Treatment was interrupted in 4 pts due to BEMA-related AEs (1 was ocular related). PR was seen in 3 pts, SD in 4 pts, and PD in 1 pt. BEMA was stopped for consent withdrawal in 1pt and PD in 2pts. Updated data will be presented at the congress.

Conclusions

This is the first time a combination of BEMA, mFOLFOX6, and NIVO is assessed. In part 1, consistent safety and PK profiles suggest no negative interaction, with no new safety signals after 6 mo.

Clinical trial identification

NCT05111626.

Editorial acknowledgement

Sahishnu Patel of Amgen Inc provided medical writing support.

Legal entity responsible for the study

Amgen Inc.

Funding

Amgen Inc.

Disclosure

Z.A. Wainberg: Financial Interests, Personal, Funding, Honoraria: Amgen, Arcus, AstraZeneca, Daiichi Sankyo, Bayer, BMS, Merck, Ipsen, Gilead, Arcus, Astellas, Seagen, Novartis; Financial Interests, Personal, Speaker, Consultant, Advisor, Advisory/Consultancy: Amgen, Arcus, AstraZeneca, Daiichi Sankyo, Bayer, BMS, Merck, Ipsen, Novartis, Gilead, Arcus, Astellas, Seagen; Financial Interests, Institutional, Research Funding: Amgen, AstraZeneca, Daiichi Sankyo, Bayer, BMS, Merck, Ipsen, Five Prime, Gilead, Arcus, Astellas, Molecular Templates, Roche/Genentech, Array/Pfizer. K. Yamaguchi: Financial Interests, Personal, Invited Speaker: Taiho Pharm; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Bristol Myers Squibb, Ono, Eli Lilly Japan; Financial Interests, Institutional, Funding: Taiho. J.A. Ajani: Financial Interests, Personal, Speaker, Consultant, Advisor, Consulting: BMS, Merck, Astellas, Taiho, More, Zymeworks, BeiGene, Dava, AstraZeneca, Acrotech, Daiichi Sankyo, Vaccinogen, Innovent, Merck Serrono, Oncotherics, Bayer, OncLive, FivePrime, Amgen, GRAIL, Novartis, Geneos, Arcus, Servier, BI, Gilead. J. Chao: Financial Interests, Personal, Full or part-time Employment, Employee: Amgen; Financial Interests, Institutional, Research Funding: Astellas Pharma, Merck, and Eterna Therapeutics; Financial Interests, Personal, Speaker, Consultant, Advisor, Consulting fees: Eli Lilly, Merck, AstraZeneca, Foundation Medicine, Daiichi Sankyo, MacroGenics, Amgen, Ono Pharmaceutical, Bristol Myers Squibb, Astellas Pharma, Turning Point Therapeutics, Silverback Therapeutics, Novartis, Coherus BioSciences, Geneos Therapeutics, Roc; Financial Interests, Personal, Advisory Board, Advisory board/DSMB: Yiviva. M. Moehler: Financial Interests, Personal, Advisory Board: BMS, Servier, Amgen, Lilly, BeiGene, Novartis, Taiho, Daiichi Sankyo, Amgen, MD; Financial Interests, Personal, Invited Speaker: MSD, BMS, Falk foundation, AIO, BeiGene, Amgen; Financial Interests, Institutional, Advisory Board: Bayer, Sanofi; Financial Interests, Personal, Other, Chair: EORTC. Y. Kang: Financial Interests, Personal, Advisory Board: ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, Merck, Roche, LISCure. E. Van Cutsem: Financial Interests, Personal, Advisory Board: AbbVie, ALX, Amgen, Array, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Terumo, Taiho, Zymeworks; Financial Interests, Institutional, Research Grant: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier. P. Yen, Y. Motii, D. Zhou, T. Murias Dos Santos: Financial Interests, Personal, Full or part-time Employment, Employee: Amgen; Financial Interests, Personal, Stocks or ownership, Stockholder: Amgen. K. Shitara: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, MSD, Taiho, Novartis, AbbVie, GSK, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan Corp, Astellas; Financial Interests, Personal, Invited Speaker: Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho, Chugai Pharmaceutical, MSD, Eisai, Amgen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.